Clinical experience in coronary bypass surgery for abciximab-treated patients
| Autor: | John H. Lemmer |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty medicine.medical_treatment Abciximab Blood Loss Surgical Emergency CABG Coronary Disease Postoperative Hemorrhage Immunoglobulin Fab Fragments Emergency surgery medicine Humans In patient cardiovascular diseases Derivation Treatment Failure Coronary Artery Bypass Emergency Treatment Chemotherapy Cardiopulmonary Bypass business.industry Antibodies Monoclonal Hemostasis Surgical Surgery surgical procedures operative medicine.anatomical_structure Bypass surgery Anesthesia Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors Artery medicine.drug |
| Zdroj: | The Annals of thoracic surgery. 70 |
| ISSN: | 0003-4975 |
| Popis: | Abciximab effectively inhibits platelet aggregation and, therefore, there is considerable concern regarding bleeding complications in patients who require coronary artery bypass graft (CABG) surgery while affected by the drug. This presentation reviews the available published literature regarding CABG in abciximab-treated patients, the clinical results of emergency CABG in 12 patients, and management suggestions for the abciximab-treated patient requiring emergency surgery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|